CTOs on the Move

Ocusoft

www.ocusoft.com

 
Ocusoft is a Rosenberg, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: $100-250 Million
  • www.ocusoft.com
  • 5311 Avenue N
    Rosenberg, TX USA 77471
  • Phone: 281.342.3350

Executives

Name Title Contact Details

Similar Companies

Turing Pharmaceuticals

Turing Pharmaceuticals is a fully integrated biopharmaceutical company focusing on patients with unmet medical needs. We are dedicated to helping patients, who often have no effective treatment options, by developing and commercializing innovative treatments.

Sucampo

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan, Switzerland and the U.K. The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.

Taro Pharmaceutical Industries

Taro Pharmaceutical Industries is a Hawthorne, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Defined Health

Defined Health is a Florham Park, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Everest Medicines

Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients in mainland China and other Asian territories. We strive to be the partner of choice for innovative companies around the world with products that address critical unmet medical needs for patients in Greater China and have a high probability of market approval. The Everest Medicines team has deep expertise and extensive track record of high quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. The company`s Series A round was led by C-Bridge Capital, a top-tier China healthcare private equity firm, with US $800 million under management.